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ABSTRACT
Objective: To determine the duration of clinical benefit
among patients with psoriatic arthritis (PsA) discontinuing
tumour necrosis factor inhibitor (TNFi) therapy while in
low disease activity (LDA), and to identify patient
characteristics associated with prolonged clinical benefit.
Methods: We performed an observational cohort study
assessing patients with PsA from the Consortium of
Rheumatology Researchers of North America (CORRONA)
registry who had discontinued TNFi after achieving LDA,
defined as clinical disease activity index (CDAI) score ≤10
and physician’s global assessment (PGA) of skin psoriasis
≤20/100. Kaplan–Meier method was used to estimate the
duration of clinical benefit.
Results: Of the 5945 patients with PsA in CORRONA, 302
patients had discontinued TNFi (n=325) while in LDA and
had follow-up data available. At time of discontinuation,
mean PsA duration was 9.8 years, mean CDAI was 3.9,
and mean duration of TNFi use was 1.5 years; 52.6% of
patients had discontinued their first TNFi. Median time to
loss of benefit was 29.2 months. 179 (55.1%) patients
had persistent benefit at their previous clinic visit. An
increased risk of losing clinical benefit was seen among
patients with higher disease activity at discontinuation
(CDAI≥3.2 vs <3.2; HR 1.43 (p=0.32)) and among
smokers (HR 1.78 (p=0.027)).
Conclusions: Patients with PsA who achieve LDA may
maintain clinical benefit after discontinuation of TNFi
therapy.

INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inﬂammatory disease with heterogeneous clinical
manifestations. Tumour necrosis factor inhibitors (TNFi) effectively treat all domains of
disease activity in PsA.1 Aggressive treatment
strategies, particularly involving the use of
TNFi, have revolutionised the treatment of
PsA resulting in low disease activity (LDA)
and remission becoming viable treatment
goals.2 3 Indeed, intensive treatment strategies in early disease have been shown to
result in better clinical outcomes in PsA.4

Key messages
What is already known about this subject?
There is a paucity of data addressing withdrawal of
biological therapy in psoriatic arthritis (PsA).
Whether tumour necrosis factor inhibitor (TNFi) can
be withdrawn in PsA in patients who have achieved
low disease activity (LDA) or remission with sustained clinical benefit remains unknown.

What does this study add?
This study provides evidence that some patients
with PsA achieving LDA may maintain clinical
benefit after discontinuation of TNFi therapy.

How might this impact on clinical practice?
It may be possible to discontinue TNFi therapy after
achieving LDA, while maintaining sustained clinical
benefit. This could have important treatment implications, particularly in light of the heavy economic
burden and potentially serious adverse effects that
may be associated with TNFi.

Owing to factors such as economic
burden, concern for drug toxicity, and
patient preferences, there has been increasing interest in the possibility that TNFi treatment may be reduced or discontinued in
patients achieving remission or LDA, with
maintenance of clinical beneﬁts. There is
some evidence for discontinuation of biological therapies in rheumatoid arthritis
(RA) with persistent clinical beneﬁt.5 6
Whether TNFi can be withdrawn in PsA with
sustained clinical beneﬁt remains unknown.
The objectives of this study were to determine the duration of sustained clinical beneﬁt
among patients with PsA who had
discontinued TNFi while in LDA, and also
to identify patient characteristics and diseaserelated factors that may be associated with
prolonged clinical beneﬁt after TNFi
discontinuation.
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PATIENTS AND METHODS
The Consortium of Rheumatology Researchers of North
America (CORRONA) registry is a large, independent,
multisite, prospective observational cohort of patients
with RA and PsA.7 We assessed patients with physiciandiagnosed PsA from 2008 to 2013 who had discontinued
TNFi after achieving LDA. Of the 5945 patients with PsA
in the CORRONA registry, there were a total of 496
TNFi discontinuations in LDA. We identiﬁed 302 eligible
patients with PsA, who had: discontinued TNFi (n=325)
while in LDA; did not have an escalation of therapy; and
had follow-up data available for analysis. Patients were
excluded if, at time of discontinuation, they had a switch
or addition of any biological or non-biological diseasemodifying antirheumatic drug (DMARD) (n=53) or if
they had an increase in dose of concomitant nonbiological DMARD or prednisone at time of TNFi discontinuation (n=93). There were 25 patients who had
no follow-up visit after TNFi discontinuation. The decision to discontinue therapy was made individually by the
patients and their treating physicians; there was no prespeciﬁed protocol for discontinuation of therapy. All
patients in the CORRONA registry provided written,
informed consent for participation in this study.
LDA was deﬁned as clinical disease activity index
(CDAI) ≤10 and physician’s global assessment (PGA) of
skin psoriasis ≤20/100. Patients were considered to have
lost clinical beneﬁt if they had: (1) an increase in CDAI
to >10; (2) an increase in skin assessment to >20; or (3)
escalation of therapy with either an increase in concomitant DMARD or prednisone doses, or initiation of prednisone, non-biological DMARD, or biological agent.
Clinical data were collected at baseline (ie, time of TNFi
discontinuation) and at loss of clinical beneﬁt or the
previous clinic visit. The CDAI used in the CORRONA
registry is based on a 28-joint count. Skin assessment was
based on physician global skin disease activity (100 mm
visual analogue scale (VAS).
Statistical analyses
Descriptive statistics are presented as means±SD for continuous variables, and frequency and percentages for
categorical variables. p Values <0.05 were considered
statistically signiﬁcant. Kaplan-Meier method was used to
estimate the median time to loss of clinical beneﬁt. Both
univariable and multivariable Cox proportional hazard
analyses were used to evaluate characteristics associated
with duration of clinical beneﬁt. Factors that were signiﬁcant at the 20% level ( p value <0.20) in the univariable
analysis were further evaluated in the multivariable
model.
RESULTS
Of the 5945 patients with PsA in the CORRONA database, there were 325 discontinuations of TNFi therapy
while in LDA in 302 patients who had follow-up data
available. The mean age was 52.6±13.1 years, 51.9% were
2

women, and mean body mass index (BMI) was 30.1±6.5
(table 1). At discontinuation, the mean duration of PsA
was 9.8±8.1 years, mean CDAI was 3.9±2.8, mean modiﬁed disease activity score (mDAS) was 2.4±0.6, and PGA
of skin psoriasis was 6.7±6.1%.
Among the patients assessed, 52.6% of patients had discontinued their ﬁrst TNFi and 31.1% had discontinued
their second TNFi. The mean duration of TNFi use prior
to discontinuation was 1.5±1.6 years. Concomitant medications at the time of TNFi discontinuation were recorded:
53.5% of patients were treated with TNFi monotherapy,
42.2% were on background methotrexate (MTX); and
5.2% took concomitant low-dose prednisone.
After withdrawal of TNFi treatment, 146 (44.9%)
patients lost clinical beneﬁt due to: increased CDAI
(31.5%); worsening skin disease (15.8%); non-biological
DMARD initiation or dose escalation (32.2%); TNFi initiation or restart (6.8%); or prednisone initiation or
dose escalation (9.6%) (table 2). Kaplan–Meier survival
estimate of median time to loss of clinical beneﬁt was
29.2 months (ﬁgure 1). At last clinic visit, 179 (55.1%)
patients had persistent clinical beneﬁt off TNFi therapy.
Patients with higher disease activity at the time of
TNFi discontinuation had increased risk of losing clinical beneﬁt HR: CDAI ≥3.2 versus <3.2, HR 1.43
( p=0.032); moderate versus low mDAS, HR 1.65
( p=0.017); patient global assessment >5 versus <5/10,
HR 1.7 ( p=0.007) (table 3). Current smokers had

Table 1 Population characteristics at time of TNFi
discontinuation (N=325)
Age (years)
Female
BMI (kg/m2)
Average
Normal
Overweight
Obese
Duration of PsA (years)
Duration of TNFi (years)
Tender joint count (mean±SD)
Swollen joint count (mean±SD)
Patient global assessment (mean±SD)
Physician global assessment (mean±SD)
CDAI (mean±SD)
mHAQ (mean±SD)
mDAS (mean±SD)
TNFi use
1st TNFi
2nd TNFi
3rd TNFi
4th TNFi
TNFi monotherapy
TNFi+MTX
TNFi+prednisone

52.6±13.1
168 (51.9%)
30.1±6.5
61 (19.1%)
113 (34.8%)
150 (46.1%)
9.8±8.1
1.5±1.6
0.66±1.13
0.38±0.83
20.2±19.0
8.6±8.6
3.9±2.8
0.20±0.32
2.4±0.6
171 (52.6%)
101 (31.3%)
46 (14.2%)
7 (2.1%)
174 (53.5%)
137 (42.4%)
24 (7.4%)

BMI, body mass index; CDAI, clinical disease activity index;
mDAS, modified disease activity score; mHAQ, modified health
assessment questionnaire; PsA, psoriatic arthritis; TNFi, tumour
necrosis factor inhibitor.
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Table 2 Distribution of events among patients with loss of clinical benefit (N=146)
Event
CDAI>10, N (%)
DMARD changes, N (%)
MTX started
MTX increased
Other DMARD started
Other DMARD increased
TNFi initiation/restart, N (%)
Prednisone, N (%)
Started
Increased
Skin assessment >20, N (%)

Total patients with loss
of clinical benefit, N=146

1st TNFi patients, N=72

2nd, 3rd, and 4th
TNFi patients, N=74

46 (31.5)

10 (13.9)

36 (48.6)

5 (3.4)
34 (23.3)
5 (3.4)
3 (2.1)
10 (6.8)

1
12
2
1
5

4 (5.4)
22 (29.7)
3 (4.1)
2 (2.7)
5 (6.8)

3 (2.1)
11 (7.5)
23 (15.8)

(1.4)
(16.7)
(2.8)
(1.4)
(6.9)

1 (1.4)
3 (4.2)
7 (9.7)

2 (2.7)
8 (10.8)
16 (21.6)

In total, 179 patients had ongoing benefit by end of study.
CDAI, clinical disease activity index; DMARD, disease-modifying antirheumatic drug; TNFi, tumour necrosis factor inhibitor.

Table 3 Univariable Cox proportional hazard analysis of
factors related to loss of clinical benefit after TNFi
discontinuation (n=325) while in LDA

Figure 1 Kaplan–Meier survival curve showing time to loss
of clinical benefit after TNFi discontinuation (N=325). LDA, low
disease activity; TNFi, tumour necrosis factor inhibitor.

signiﬁcantly higher risk for loss of clinical beneﬁt
(smokers versus non-smokers), HR 1.78 ( p=0.027) in
univariable and multivariable analysis. In the multivariable model, current smoking was associated with higher
risk of losing clinical beneﬁt HR 1.76, 95% CI (1.13 to
2.27) while CDAI >3.2 versus <3.2 also appeared to
convey increased risk for loss of clinical beneﬁt HR 1.42
(0.99 to 2.03). Age and gender did not alter this risk in
the multivariable model. The number of prior TNFi
used and overweight or obese status did not signiﬁcantly
affect loss of clinical beneﬁt in our cohort.
DISCUSSION
Advances in highly effective therapies have led to
improved clinical outcomes in PsA, making LDA and
remission achievable goals. Since TNFi are associated
with both a high ﬁnancial burden and an increased risk
of potentially life-threatening adverse events, the need
for maintenance therapy with these biological agents
has been challenged. As a result, there is increasing
interest into whether TNFi could be reduced or
Huynh DH, et al. RMD Open 2017;3:e000395. doi:10.1136/rmdopen-2016-000395

Characteristic at
discontinuation

Univariable
HR (95% CI)

p
Value

Age (<53 years (ref))
Gender (male (ref))
Smoker (never (reference))
Former
Current
BMI (overweight vs normal
(ref))
Duration of PsA (>1 vs
≤1 year (ref))
CDAI (<3.2 (ref) vs ≥3.2)
TJC (0 (ref) vs >0)
SJC (0 (ref) vs >0)
Patient global assessment
(<5 (ref) vs ≥5 ref)
Physician global
assessment (<15 (ref) vs
≥15)
mHAQ (0 (ref) vs >0 ref)
mDAS (moderate vs low)

0.74 (0.54 to 1.04)
1.02 (0.74 to 1.42)

0.086
0.879

1 (0.67 to 1.48)
1.78 (1.167 to 2.65)
0.85 (0.57 to 1.27)

0.027
0.428

0.83 (0.44 to 1.58)

0.575

1.43 (1.03
1.32 (0.95
0.83 (0.55
1.70 (1.16

to 2.00)
to 1.85)
to 1.24)
to 2.51)

0.032
0.095
0.367
0.007

1.13 (8.82 to 1.58)

0.454

0.85 (0.61 to 1.18)
1.65 (1.09 to 2.49)

0.338
0.012

Factors that were significant at the 20% level (p value <0.20) were
further evaluated in a multivariable analysis model, although no
new differences arose.
BMI, body mass index; CDAI, clinical disease activity index;
LDA, low disease activity; mDAS, modified disease activity score;
mHAQ, modified health assessment questionnaire; PsA, psoriatic
arthritis; SJC, swollen joint count; TJC, tender joint count;
TNFi, tumour necrosis factor inhibitor.

discontinued while maintaining clinical beneﬁt in
patients with PsA who have achieved good clinical outcomes on these medications.
There is a paucity of data looking at tapering strategies—through either dose reduction or drug discontinuation—for TNFi in PsA, and the results are not
straightforward. In a single-centre, prospective study of
the 76 patients with PsA treated with adalimumab,
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88.6% of patients maintained remission after halving the
dose of TNFi therapy over a follow-up period of
28.9 months.8 Thus sustained remission through
decreasing the dose of TNFi appears possible. The
results with drug discontinuation are less certain. In a
small study of 26 patients, stopping conventional and
biological DMARDs resulted in a high incidence of early
disease recurrence (76.9%), suggesting that drug-free
remission was not possible.9 In contrast, a prospective
study of 236 patients with PsA with peripheral joint
involvement, showed that remission was possible in 24%
of patients after the interruption of therapy and was signiﬁcantly more common in patients who received TNFi
than traditional DMARDs.10 It should be noted that
relapse did occur in 49% of patients after 12±2.4 months
of treatment discontinuation, although these patients
were not maintained on non-biological DMARDs.
Data from our cohort suggests TNFi discontinuation
in patients with PsA with LDA can be associated with sustained clinical beneﬁt (median 29.2 months). While 146
(44.9%) patients lost clinical beneﬁt, only 10 (6.8%)
were restarted on TNFi, while the others were managed
with non-biological DMARDs and prednisone. Thus, this
strategy could have a signiﬁcant impact on decreasing
the economic burden and limiting the risks associated
with prolonged TNFi exposure.
Predictors of sustained remission after TNFi discontinuation have not yet been conﬁrmed.11 It looks from
our cohort that smokers and patients with worse disease
activity at the time of discontinuation of TNFi fare worse.
In contrast, disease duration, the number of prior TNFi
used, and BMI did not seem to affect the outcome.
Further studies will be required to identify predictors of
prolonged remission after discontinuation of TNFi.
A potential limitation of our study is that the reason
for discontinuation of TNFi in the study population is
not known. We excluded patients who had any escalation of therapy (ie, switch or addition of any other biological or non-biological DMARD, or increase in dose of
concomitant non-biological DMARD or prednisone) at
the time of discontinuation, but we cannot account for
reasons for discontinuation other than LDA (eg, adverse
events, ﬁnancial burden, etc). A second limitation of
this study is our use of CDAI with a 28-joint count. The
CDAI is a composite disease activity index developed for
RA, but frequently extrapolated to and validated in PsA;
however, it does not include the ankles and feet, which
are commonly affected in PsA.

4

In summary, patients with PsA who achieve LDA on
treatment may maintain persistent clinical beneﬁt after
the discontinuation of TNFi. Patients with higher disease
activity at the time of discontinuation and smokers may
have less success at stopping TNFi therapy. Whether biological therapy can be reduced or discontinued in the
long term requires further study in controlled withdrawal trials.
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